Biote Reports First Quarter 2025 Financial Results

About this update from Biote Corp.

[{"type":"text","content":"Strong financial performance driven in part by increased gross margin from vertical integration","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"Announces organizational restructuring to drive sustainable growth and build long-term value","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"Maintains 2025 financial outlook","length":32,"tagName":"p","attribs":{}},{"type":"text","content":"First Quarter 2025 Financial Highlights","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $49.0 million","length":24,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit margin of 74.3%","length":28,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period","length":252,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1%","length":70,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"IRVING, Texas, May 07, 2025--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2025.","length":284,"tagName":"p"},{"type":"text","content":""Biote’s first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business," said Bret Christensen, Biote Chief Executive Officer. "Total first quarter revenue increased 4.7% year-over-year, primarily due to a 25.5% increase in dietary supplements revenue. Procedure revenue decreased 3.6% year-over-year, reflecting reduced commercial effectiveness and a slowdown in new clinic additions. We are focused on driving new clinic growth throughout our network."","length":587,"tagName":"p"},{"type":"text","content":"Mr. Christensen continued, "Last year, Biote embarked on an ambitious plan designed to st...

More updates from Biote Corp.